©2022 Stanford Medicine
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Trial ID: NCT02531425
Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) followed immediately by electroporation (EP), into accessible tumor lesions. IT-pIL12-EP will be administered in Days 1, 5, and 8 of the single 28-day cycle.
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
- Patients with histologically confirmed diagnosis of locally-advanced, inoperable,
metastatic and/or treatment-refractory triple negative breast cancer (TNBC).
*Treatment refractory disease is defined as the persistence of tumor lesions following
at least one intervention that may include chemotherapy, radiation and/or surgery, or
any combination thereof. *Patients must have both ER and PR staining < 5% and be
HER2-negative. Patients with ER or PR staining of 5-10%, but who have historically
been treated as TNBC may also be enrolled. *Patients must not have disease that, in
the opinion of the investigator, is considered amenable to potentially curative
- Age ≥ 18 years.
- ECOG Performance Status of 0-1.
- Life expectancy ≥ 6 months.
- Patients may have had radiation therapy, but must have progressive disease after
radiation therapy if the lesions to be treated are within the radiation field.
Radiation treatment must be completed ≥ 4 weeks prior to Cycle 1 Day 1.
- Adequate hepatic function with total bilirubin and ALT < 1.5X the upper limit of
normal (ULN), except in patients with Gilbert's Syndrome must have a total bilirubin <
3X ULN and ALT < 3X ULN. In cases of known liver metastases, ALT ≤ 5X ULN is
acceptable (total bilirubin must be < 1.5X ULN).
- Adequate renal function, estimated or calculated creatinine clearance of > 50 mL/min
(calculated using the formula of Cockcroft and Gault) -or- serum creatinine ≤ 2.0
- Adequate hematological function, defined as ANC ≥ 1,500/mm3, Hb ≥ 9.0 g/dL, and
platelet count ≥ 100,000/mm3.
- Lesions that are accessible for injection and electroporation, defined as cutaneous or
- At least 2 anatomically distinct lesions accessible for biopsy.
- Must consent to study-specific biopsies at two separate timepoints: pre-treatment
(Screening) and post-treatment (Day 28 or EOS).
- Tumor lesions in the CNS are permitted but lesions must have been stable for at least
3 months prior to Cycle 1 Day 1 (C1D1). Stable CNS lesions are defined as not
requiring steroid prophylaxis or other medications to prevent seizures or other
complications associated with CNS lesions and no evidence of worsening of CNS disease.
- Female patients of childbearing potential must have a negative serum or urine
pregnancy test within 3 days prior to C1D1 and agree to use dual methods of
contraception during the study and for a minimum of 30 days following the last
treatment. Post menopausal females (>45 years old and without menses for > 1 year) and
surgically sterilized females are exempt from these requirements.
Male patients must use an effective barrier method of contraception during the study and
for a minimum of 30 days following the last treatment if sexually active with a female of
- Resolution of all treatment-related toxicities, except alopecia, anemia and
neuropathy, from any previous cancer therapy to ≤ Grade 1 prior to the first dose of
- Ability to provide written informed consent.
- Any other current or previous malignancy within the past three years that, in the
opinion of the Principal Investigator, will interfere with study-specific objectives.
- Patients with electronic pacemakers or defibrillators.
- Chemotherapy or hormonal therapy for anti-cancer treatment within 28 days prior to
Cycle 1 Day 1.
- Immunotherapy or biological therapy (e.g., monoclonal antibodies) within 28 days prior
to Cycle 1 Day 1, unless pre-approval is obtained from the Sponsor Medical Monitor.
- Treatment with unapproved investigational therapeutic agent within 28 days prior to
Cycle 1 Day 1, unless pre-approval is obtained from the Sponsor Medical Monitor.
- Patients receiving systemic steroid therapy for a chronic inflammatory condition
(e.g., rheumatoid arthritis, Crohn's Disease, etc.). Topical steroids are also
excluded. Nasal and inhaled steroids are permitted.
- Unstable/inadequate cardiac function:
- symptomatic ischemia
- uncontrolled or clinically significant conduction abnormalities; first degree AV
block or asymptomatic LAFB/RBBB are eligible
- myocardial infarction in the previous six months
- congestive heart failure (New York Heart Association class III to IV)
- Major surgery within 28 days prior to C1D1.
- Infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks
prior to C1D1.
- Patients who are known to have HIV infection/seropositivity.
- Active Hepatitis A, B, or C infection or known to be positive for HCV RNA or HBV
surface antigen. Patients who have been vaccinated against Hepatitis B and who are
positive for ONLY the Hepatitis B surface antibody are permitted to participate in the
- Serious psychiatric or medical conditions that could interfere with treatment or
- Patients who are pregnant or lactating.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305